secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2026-04-02T23:59:59+00:00
Accession:  0001628280-26-023176
Event type: regulatory
Sentiment:  negative
Materiality: 0.40
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen falls below Nasdaq audit committee minimum after director resignation
------------------------------------------------------------------------------

- Ms. Mary Rotunno resigned from the Board effective April 1, 2026, reducing Audit Committee from 3 to 2 members.
- Company notified Nasdaq of non-compliance with Listing Rule 5605(c)(2) requiring at least three audit committee members.
- Nasdaq listing not affected; cure period of up to one year from resignation date to regain compliance.
- Board plans to fill vacancy and return to compliance within the cure period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000162828026023176/0001628280-26-023176-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000162828026023176/vtgn-20260401.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-023176

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer